Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 (telitacicept) plus standard therapy vs placebo in moderate-to-severe SLE
CTR20150877Phase 2Completed
- Sponsor
- RemeGen
- Start
- Jan 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in systemic lupus erythematosus (SLE), sponsored by RemeGen. Started Jan 2016; status: completed.
02
Drugs
telitacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20150877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150877.